This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • Randomized Controlled Trial  • Alert me on articles by topic

Arch Neurol. 2002;59:27-28.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

BIOMEDICAL RESEARCH is becoming more complex as a result of involvement by individual investigators, universities, commercial research units, and industry. Financial conflicts of interest have been the subject of many editorials, and most peer-reviewed journals now require any conflicts to be identified and explained when authors submit their manuscripts for publication. Clear statements of industry-sponsored research and author participation in corporate activities are required for the evaluation of a manuscript. Full disclosure of financial interests by authors is essential to retain public trust in biomedical research, the peer review process, and the integrity of the authors and universities.¹ We already require each author to sign a statement of his or her financial arrangements with public, private, and industry sources of support. These declarations alert the editor, reviewer, and physician-reader to any potential bias in the interpretation and presentation of the data. Patients' lives may depend on an accurate and complete . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Recommendations for the Relationship Between Sponsors and Investigators in the Design and Conduct of Clinical Stroke Trials
Donnan et al.
Stroke 2003;34:1041-1045.
ABSTRACT | FULL TEXT  

Full Access for Government-Funded Clinical Trials
Meyer
Arch Neurol 2002;59:1664-1664.
FULL TEXT